47 Spam-Free Article(s) Found
https://www.zacks.com/stock/news/2209986/here-s-why-you-should-buy-align-technology-algn-stock-now?cid=CS-ZC-FT-analyst_blog|rank_focused-2209986
Jan 15, 2024 - Investors remain optimistic about Align Technology (ALGN) due to the progress in the Invisalign portfolio and highly favorable solvency.
zc:2918754114787033836
0
https://www.zacks.com/stock/news/2209990/quest-diagnostics-dgx-inks-new-deal-with-ultima-genomics?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2209990
Jan 15, 2024 - Quest Diagnostics' (DGX) new partnership is likely to leverage its oncology expertise and national scale.
zc:5913127828694155687
0
https://www.zacks.com/stock/news/2211543/abbott-s-abt-innovations-aid-macroeconomic-issues-stay?cid=CS-ZC-FT-analyst_blog|zer_report_update-2211543
Jan 17, 2024 - Abbott (ABT) is successfully continuing the rollout of Alinity, the company's fully integrated and automated molecular diagnostics analyzer.
zc:-5149813611187914168
0
https://www.zacks.com/stock/news/2212281/penumbra-pen-rides-on-vascular-arm-strength-amid-fx-woes?cid=CS-ZC-FT-analyst_blog|zer_report_update-2212281
Jan 18, 2024 - Penumbra's (PEN) Vascular business is demonstrating strong growth, banking on a rapid increase in sales of vascular thrombectomy products in the United States.
zc:1344420748921052212
0
https://www.zacks.com/stock/news/2216440/healthequity-inc-hqy-hit-a-52-week-high-can-the-run-continue?cid=CS-ZC-FT-52_week_high-2216440
Jan 26, 2024 - HealthEquity (HQY) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
zc:-5148480899851748366
0
https://www.zacks.com/stock/news/2239310/healthequity-hqy-reports-next-week-wall-street-expects-earnings-growth?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_9-2239310
Mar 12, 2024 - HealthEquity (HQY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
zc:-5062835243638069446
0
https://www.zacks.com/stock/news/2243114/compared-to-estimates-healthequity-hqy-q4-earnings-a-look-at-key-metrics?cid=CS-ZC-FT-fundamental_analysis|nfm-2243114
Mar 19, 2024 - The headline numbers for HealthEquity (HQY) give insight into how the company performed in the quarter ended January 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
zc:8540669521700491736
0